The post Pi Network News: Pi App Studio Adds Test-Pi Payments and Low-Cost Deployment Option appeared first on Coinpedia Fintech News The Pi Network has introducedThe post Pi Network News: Pi App Studio Adds Test-Pi Payments and Low-Cost Deployment Option appeared first on Coinpedia Fintech News The Pi Network has introduced

Pi Network News: Pi App Studio Adds Test-Pi Payments and Low-Cost Deployment Option

Pi Network News Today

The post Pi Network News: Pi App Studio Adds Test-Pi Payments and Low-Cost Deployment Option appeared first on Coinpedia Fintech News

The Pi Network has introduced a series of updates to its Pi App Studio at the start of 2026, directed at expanding access to app creation and increasing the use of Pi within applications built on its ecosystem.

The updates include simplified payment integration, an ad-supported option for deploying apps, and a community feedback initiative designed to guide future development of the platform.

Payments Integration Added for App Creators

One of the main changes is the addition of in-app payment support within Pi App Studio. The feature allows creators to integrate Pi-based payments into their applications without writing code. Payments are currently limited to Test-Pi and apply only within active app sessions, such as purchasing items or unlocking features during a single use.

The company said the feature removes technical barriers that previously required developer-level knowledge, even as Pi Network has worked to reduce integration complexity through developer tools. Persistent purchases across sessions are not yet supported, but the framework is intended to prepare apps for future mainnet-enabled payments.

Ad-Supported App Deployment Expands Access

Pi App Studio has also introduced an option that allows creators to deploy app iterations by watching advertisements instead of paying Pi. This feature is aimed at users who are not yet migrated to the mainnet or who have limited Pi balances.

According to Pi Network, ad revenue does not cover the full cost of app generation and server deployment, but is being used as a subsidy to lower barriers to participation while limiting spam and misuse. The company noted the feature could be adjusted or removed in the future depending on economic sustainability.

Community Feedback Initiative Launched

Alongside the technical updates, Pi Network has launched a community-wide event inviting users to provide feedback on existing App Studio applications through a survey. Responses are intended to help identify useful apps and inform future improvements to the platform’s tools and features.

The company said feedback from users would be used to refine App Studio functionality and guide decisions around app development support.

Broader Push for Utility in 2026

The updates reflect Pi Network’s broader effort to increase real-world utility within its ecosystem by enabling non-technical users to build functional applications. By lowering costs and simplifying payments, the company aims to expand participation in app creation while increasing opportunities for Pi to be used within apps.

Pi Network did not provide a timeline for when Test-Pi payments would transition to full mainnet functionality but said the current changes lay the groundwork for future expansion.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

Trump Filed a Lawsuit Against JPMorgan Chase And Its CEO Over Debanking

U.S. President Donald Trump filed a lawsuit against JPMorgan Chase and its CEO Jamie Dimon personally, accusing the institution of deliberate debanking. The politician
Share
Incrypted2026/01/23 15:59
Here’s why Polygon price is at risk of a 25% plunge

Here’s why Polygon price is at risk of a 25% plunge

Polygon price continued its freefall, reaching its lowest level since April 21, as the broader crypto sell-off gained momentum. Polygon (POL) dropped to $0.1915, down 32% from its highest point in May and 74% below its 2024 peak. The crash…
Share
Crypto.news2025/06/19 00:56
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26